Boehringer Ingelheim said yesterday that results from a study of its Spiolto Respimat inhaler showed benefits including improving symptoms and lung function in treating chronic obstructive pulmonary disease.
The Spiolto Respimat is a soft-mist inhaler designed for the treatment of airflow obstruction in patients with COPD.
A pooled analysis exploring COPD treatment with the tiotropium-based Spiolto Respimat showed optimizing bronchodilation with tiotropium/olodaterol led to improvements in lung function, health status and breathlessness. A comparative analysis found that the treatment surpassed all others in terms of efficacy, while also producing fewer serious adverse cardiovascular events.
Get the full story at our sister site, Drug Delivery Business News.